Document is current
Any future updates will be listed below
-
Authors
Rajwa, Pawel https://orcid.org/0000-0003-4073-6584
Yanagisawa, Takafumi https://orcid.org/0000-0002-7410-0712
Heidegger, Isabel
Zattoni, Fabio https://orcid.org/0000-0002-4178-373X
Marra, Giancarlo
Soeterik, Timo F. W.
van den Bergh, Roderick C. N.
Valerio, Massimo
Ceci, Francesco https://orcid.org/0000-0001-9785-5248
Kesch, Claudia V. https://orcid.org/0000-0002-2656-2664
Kasivisvanathan, Veeru https://orcid.org/0000-0002-0832-382X
Laukhtina, Ekaterina https://orcid.org/0000-0002-8953-0272
Kawada, Tatsushi https://orcid.org/0000-0002-8369-9712
Nyiriadi, Peter
Trinh, Quoc-Dien
Chlosta, Piotr
Karakiewicz, Pierre I.
Ploussard, Guillaume
Briganti, Alberto
Montorsi, Francesco
Shariat, Shahrokh F. https://orcid.org/0000-0002-6627-6179
Gandaglia, Giorgio
,
van den Bergh, Roderick C. N.
-
Funding
Funding for this research was provided by:
European Association of Urology
- License Information
-
More Information
Article History
Received: 29 July 2022
Revised: 13 September 2022
Accepted: 30 September 2022
First Online: 25 October 2022
Competing interests
: PR and GG served as a speaker and/or consultant and/or advisory board for Janssen, SFS has served as a speaker and/or consultant and/or advisory board for Astellas, Astra Zeneca, BMS, Ferring, Ipsen, Janssen, Lilly, MSD, Olympus, Roche, Sanofi, Takeda, and Urogen. CK has received consultant fees from Apogepha, research funding from AAA/Novartis and Curie Therapeutics and compensation for travel from Janssen.
